Journal of Clinical Oncology
Articles in this Issue
REJOICE-Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer.
TPS5637 Background: Platinum-resistant ovarian cancer (PROC) is associated with poor outcomes. Standard-of-care single-age...
Trends and disparities in prostate cancer and tobacco use–related mortality among adults aged ≥55 years in the United States, 1999-2024: A CDC WONDER analysis.
e17082 Background: Prostate cancer (PC) is one of the leading causes of death among men in the United States and represent...
Real-world cumulative exposure of various endocrine-disrupting chemicals and association with breast cancer risk via common carcinogenic pathway.
630 Background: Convergent evidence suggests carcinogenicity of endocrine disrupting chemicals (EDCs). But there is a lack...
Advancing breast cancer diagnosis in rural Kenya: Bridging histopathological gaps toward Global Breast Cancer Initiative (GBCI) goals.
e12717 Background: Breast cancer disproportionately impacts low-middle income countries such as Kenya. In Kisumu over 75%...
Sex-associated differences in osimertinib pharmacokinetics among Asian patients with non-small cell lung cancer.
3094 Background: Osimertinib is an oral, third-generation tyrosine kinase inhibitor (TKI) used in the treatment of epiderm...
Efficacy and safety of a temperature-controlled oral cryotherapy device in preventing oral mucositis among patients receiving high-risk anticancer regimens.
12154 Background: Oral mucositis (OM) is a severe dose-limiting toxicity in cancer patients receiving intensive chemothera...
Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 to inform resistance to immunotherapy in HCC.
2567 Background: First-line immune checkpoint inhibitor (ICI) therapy has contributed to improved outcomes in hepatocellul...
The effect of adjuvant therapy on survival in gastric cancer patients achieving pathologic complete response after neoadjuvant immunochemotherapy.
e16120 Background: Perioperative immunotherapy has significantly increased pathologic complete response (pCR) rates in loc...
Empowering patients with multiple myeloma through the INSIST! program: Outcomes of biomarker testing education.
e19545 Background: Multiple myeloma is a biologically complex hematologic malignancy in which biomarker testing is essenti...
Efficacy and safety of mixed formulation aprepitant and palonosetron (QLM2010) for prevention of cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized, double-blind, double-dummy, positive-controlled phase III study.
12147 Background: QLM2010, a novel fixed-dose intravenous antiemetic combination of aprepitant and palonosetron (PALO), ca...
Association between intratumoral <i>Fusobacterium nucleatum</i> levels and clinical outcomes in esophageal squamous cell carcinoma: A comprehensive systematic review.
e16081 Background: Intratumoral Fusobacterium nucleatum (F. nuc) is a key microbial participant in gastrointestinal malign...
Oral mucositis as a predictor of differential long-term adverse events and mortality in breast cancer patients treated with monoclonal antibody-drug conjugates: Evidence from a propensity score-matched cohort comparison using real-world data from 88 U.S Healthcare organizations.
e12752 Background: Monoclonal antibody-drug conjugates (mADCs) are a cornerstone of advanced breast cancer treatment, but...
Clinical risk factors for polyneuropathy in patients receiving immune checkpoint inhibitor therapy.
e24174 Background: This study investigates neurological toxicities, particularly polyneuropathy, as immune-related adverse...
Radical treatment of extraskeletal myxoid chondrosarcoma: A retrospective analysis of long-term outcomes and inflammatory prognostic factors.
e23561 Background: Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare soft tissue sarcoma characterised by recurre...
Data from a real-world study: Association of CDCP1 expression level with survival outcomes in mCRC patients treated with bevacizumab or cetuximab plus chemotherapy.
3593 Background: CUB domain-containing protein 1 (CDCP1) is a transmembrane protein shown to be over-expressed in colorect...
MC1923: Phase II durvalumab plus lurbinectedin in platinum-resistant relapsed extensive-stage small cell lung cancer after prior chemoimmunotherapy (cohort B).
8094 Background: Patients with extensive-stage small cell lung cancer (ES-SCLC) who progress after platinum-based chemothe...
Phase Ib/II clinical study of adebrelimab combined with decitabine, nab-paclitaxel, and gemcitabine as first-line (IL) treatment for metastatic pancreatic cancer (mPC).
4200 Background: Epigenetic enzyme inhibitors may synergize with immunotherapy by modulating antigen presentation and enha...
Clinicopathologic characteristics and treatment outcomes of adenoid cystic carcinoma (ACC) by different primary sites.
6121 Background: Although ACC commonly arises in the salivary glands, nearly 40% arise at extra-salivary sites and are oft...
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
500 Background: Tumor gene expression tests are widely used to assist adjuvant chemotherapy decisions for women wi...
Clinical-stage AI-enabled therapeutic assets: An industry-wide analysis of scale, clinical progression, and company characteristics.
11072 Background: Artificial intelligence (AI) is increasingly applied in therapeutic discovery and has driven substantial...
PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative tumors: A meta-analysis.
e14568 Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) can enhance antitumor immunity and potentially improve...
Patient-reported socioeconomic vulnerability and treatment delivery in patients receiving oral anticancer drugs within the Oncoral outpatient care program.
e23272 Background: Socioeconomic vulnerability has been identified as a major determinant of cancer outcomes and treatment...
Study design of OMAHA-015: A phase 2 basket study of steroidogenesis inhibitor opevesostat in participants with selected solid tumors.
TPS3183 Background: Opevesostat (MK-5684; ODM-208), an oral steroidogenesis inhibitor, selectively inhibits CYP11A1, block...
Longitudinal <i>MTAP</i> copy number alteration (CNA) in NSCLC with repeated biopsy samples.
e23348 Background: MTAP homozygous deletion (HomD) is associated with inferior survival outcome and re...
Impact of hematological parameters and timing of immunotherapy administration on outcomes in first-line advanced non–small cell lung cancer: A retrospective real-world study.
e20575 Background: Baseline hematological parameters have emerged as potential prognostic biomarkers in patients with adva...